Edward Kerwin

7.5k total citations · 2 hit papers
182 papers, 4.9k citations indexed

About

Edward Kerwin is a scholar working on Pulmonary and Respiratory Medicine, Physiology and Civil and Structural Engineering. According to data from OpenAlex, Edward Kerwin has authored 182 papers receiving a total of 4.9k indexed citations (citations by other indexed papers that have themselves been cited), including 156 papers in Pulmonary and Respiratory Medicine, 114 papers in Physiology and 8 papers in Civil and Structural Engineering. Recurrent topics in Edward Kerwin's work include Chronic Obstructive Pulmonary Disease (COPD) Research (118 papers), Asthma and respiratory diseases (114 papers) and Inhalation and Respiratory Drug Delivery (77 papers). Edward Kerwin is often cited by papers focused on Chronic Obstructive Pulmonary Disease (COPD) Research (118 papers), Asthma and respiratory diseases (114 papers) and Inhalation and Respiratory Drug Delivery (77 papers). Edward Kerwin collaborates with scholars based in United States, Canada and United Kingdom. Edward Kerwin's co-authors include Eric E. Ungar, William W. Busse, Stephen T. Holgate, Yun Chon, Shao‐Lee Lin, JingYuan Feng, Joseph Lin, Anthony D’Urzo, Cynthia Caracta and Alison Church and has published in prestigious journals such as Nature Medicine, SHILAP Revista de lepidopterología and American Journal of Respiratory and Critical Care Medicine.

In The Last Decade

Edward Kerwin

172 papers receiving 4.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Damping of Flexural Waves by a Constrained Viscoelastic Layer

1959 582 citations Edward Kerwin profile →
Randomized, Double-Blind, Placebo-controlled Study of Brodalumab, a Human Anti–IL-17 Receptor Monoclonal Antibody, in Moderate to Severe Asthma

2013 506 citations William W. Busse, Stephen T. Holgate et al. American Journal of Respiratory and Critical Care Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Edward Kerwin United States	30	3.1k	3.0k	699	693	515	182	4.9k
Namho Kim South Korea	27	207 0.1×	122 0.0×	220 0.3×	435 0.6×	133 0.3×	135	2.5k
H. Baier Germany	22	162 0.1×	512 0.2×	171 0.2×	516 0.7×	29 0.1×	161	2.2k
Tomoharu Shimizu Japan	30	172 0.1×	526 0.2×	227 0.3×	41 0.1×	471 0.9×	199	3.0k
Shih‐Hung Tsai Taiwan	28	189 0.1×	606 0.2×	295 0.4×	78 0.1×	173 0.3×	199	3.3k
Xiaoming Zhang United States	31	63 0.0×	429 0.1×	942 1.3×	384 0.6×	47 0.1×	233	4.1k
James F. Antaki United States	42	236 0.1×	1.0k 0.3×	250 0.4×	69 0.1×	19 0.0×	277	5.6k
Thomas J. Martin United States	24	264 0.1×	816 0.3×	156 0.2×	53 0.1×	65 0.1×	130	2.7k
J. J. Fredberg United States	27	691 0.2×	2.1k 0.7×	42 0.1×	7 0.0×	95 0.2×	55	2.9k
Shinichi Goto Japan	31	285 0.1×	611 0.2×	22 0.0×	25 0.0×	165 0.3×	282	4.0k
Begoña Calvo Spain	41	61 0.0×	458 0.2×	535 0.8×	130 0.2×	273 0.5×	211	5.0k

Countries citing papers authored by Edward Kerwin

Since Specialization

Citations

This map shows the geographic impact of Edward Kerwin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Edward Kerwin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Edward Kerwin more than expected).

Fields of papers citing papers by Edward Kerwin

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Edward Kerwin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Edward Kerwin. The network helps show where Edward Kerwin may publish in the future.

Co-authorship network of co-authors of Edward Kerwin

This figure shows the co-authorship network connecting the top 25 collaborators of Edward Kerwin. A scholar is included among the top collaborators of Edward Kerwin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Edward Kerwin. Edward Kerwin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Kerwin, Edward, et al.. (2025). Rademikibart Treatment for Moderate-to-Severe Uncontrolled Asthma: A Phase 2B Randomized Clinical Trial. American Journal of Respiratory and Critical Care Medicine. 211(5). 749–758. 4 indexed citations

Oppenheimer, John, Huib A.M. Kerstjens, Louis‐Philippe Boulet, et al.. (2024). Characterization of Moderate and Severe Asthma Exacerbations in the CAPTAIN Study. The Journal of Allergy and Clinical Immunology In Practice. 12(9). 2372–2380.e5. 1 indexed citations

Kerwin, Edward, et al.. (2024). Comparison of Systemic Exposure Between Epinephrine Delivered via Metered-Dose Inhalation and Intramuscular Injection. Journal of Aerosol Medicine and Pulmonary Drug Delivery. 38(2). 71–82.

Nathan, Robert A., Louis‐Philippe Boulet, Huib A.M. Kerstjens, et al.. (2020). CAPTAIN STUDY: EFFECT OF BASELINE LUNG FUNCTION ON RESPONSE TO TRIPLE THERAPY IN PATIENTS WITH ASTHMA INADEQUATELY CONTROLLED ON INHALED CORTICOSTEROID/LONG-ACTING BETA2-AGONIST THERAPY. CHEST Journal. 158(4). A2621–A2625.

Stephenson, Judith J., et al.. (2020). Observational Real-World Study to Assess Clinical Characteristics and Device Satisfaction in Patients with COPD Treated with Glycopyrrolate/eFlow® CS. International Journal of COPD. Volume 15. 1713–1727. 6 indexed citations

Kerwin, Edward, et al.. (2020). Pharmacokinetic Study of Epinephrine Hydrofluoroalkane (Primatene MIST) Metered-Dose Inhaler. Journal of Aerosol Medicine and Pulmonary Drug Delivery. 33(5). 282–287. 2 indexed citations

Ng, Dik, Edward Kerwin, Martha V. White, et al.. (2019). Clinical Bioequivalence of Wixela Inhub and Advair Diskus in Adults With Asthma. Journal of Aerosol Medicine and Pulmonary Drug Delivery. 33(2). 99–107. 11 indexed citations

Kerwin, Edward, Thomas M. Siler, Samir Arora, et al.. (2018). Efficacy, safety, and pharmacokinetics of budesonide/formoterol fumarate delivered via metered dose inhaler using innovative co-suspension delivery technology in patients with moderate-to-severe COPD. International Journal of COPD. Volume 13. 1483–1494. 2 indexed citations

Kerwin, Edward, et al.. (2018). Effect of background long-acting beta2-agonist therapy on the efficacy and safety of a novel, nebulized glycopyrrolate in subjects with moderate-to-very-severe COPD. International Journal of COPD. Volume 13. 2917–2929. 7 indexed citations

10.

Kerwin, Edward, et al.. (2017). The effect of umeclidinium on lung function and symptoms in patients with fixed airflow obstruction and reversibility to salbutamol: A randomised, 3-phase study. Respiratory Medicine. 131. 148–157. 10 indexed citations

11.

Ferguson, Gary T., et al.. (2017). In Vitro Characterization of the eFlow Closed System Nebulizer with Glycopyrrolate Inhalation Solution. Journal of Aerosol Medicine and Pulmonary Drug Delivery. 31(3). 162–169. 24 indexed citations

12.

Kerwin, Edward, Tim Ayers, Angel FowlerTaylor, et al.. (2015). QVA149 Demonstrated Significant Improvement in Lung Function Compared With Placebo and Its Monocomponents: Pooled Analysis From the FLIGHT1 and FLIGHT2 Studies. CHEST Journal. 148(4). 741A–741A. 1 indexed citations

13.

Siler, Thomas M., et al.. (2014). Efficacy and Safety of Once-Daily Umeclidinium Added to Fluticasone Furoate/Vilanterol in Chronic Obstructive Pulmonary Disease: Results of Two Replicate Randomized 12-Week Studies. CHEST Journal. 146(4). 340A–340A. 3 indexed citations

14.

Decramer, Marc, Antonio Anzueto, Edward Kerwin, et al.. (2013). Efficacy and safety of umeclidinium/vilanterol compared with umeclidinium or tiotropium in COPD. European Respiratory Journal. 42(Suppl 57). P3640–P3640. 1 indexed citations

15.

Kerwin, Edward, et al.. (2013). Dose-Ranging Study of 2 Fixed-Dose Combinations of Twice-Daily Aclidinium Bromide Plus Formoterol in Patients With Moderate to Severe COPD. CHEST Journal. 144(4). 747A–747A. 3 indexed citations

16.

Busse, William W., Stephen T. Holgate, Edward Kerwin, et al.. (2013). Randomized, Double-Blind, Placebo-controlled Study of Brodalumab, a Human Anti–IL-17 Receptor Monoclonal Antibody, in Moderate to Severe Asthma. American Journal of Respiratory and Critical Care Medicine. 188(11). 1294–1302. 506 indexed citations breakdown →

17.

Kerwin, Edward, et al.. (2012). Efficacy and safety characteristics of mometasone furoate/formoterol fumarate fixed-dose combination in subjects with moderate to very severe COPD: findings from pooled analysis of two randomized, 52-week placebo-controlled trials. SHILAP Revista de lepidopterología. 2 indexed citations

18.

Kerwin, Edward, Anthony D’Urzo, Arthur F. Gelb, et al.. (2010). Efficacy and Safety of Twice-Daily Aclidinium Bromide in Patients With COPD: Results From ACCORD COPD I. CHEST Journal. 138(4). 469A–469A. 4 indexed citations

19.

Wenzel, Sally E., Peter J. Barnes, Eugene R. Bleecker, et al.. (2009). A Randomized, Double-blind, Placebo-controlled Study of Tumor Necrosis Factor-α Blockade in Severe Persistent Asthma. American Journal of Respiratory and Critical Care Medicine. 179(7). 549–558. 370 indexed citations

20.

Kerwin, Edward, Martha Tarpay, Michael Noonan, et al.. (2006). Safety and Efficacy of a New Albuterol Hydrofluoroalkane Formulation for Treating Asthma Symptoms in Children Two to Less Than Four Years of Age. Pediatric Asthma Allergy & Immunology. 19(2). 81–90. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact